Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1390 + SBRT in Metastatic Solid Tumors
NCT05678010Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2023
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azd1390 in solid tumor (8 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Toxicities related to study treatment at 1 year. Started May 2023; status: active, not recruiting.
02
Drugs
azd1390
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05678010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678010.